SCHEMBL4423587

SCHEMBL4423587

O=S(=O)(c1ccc2ccccc2c1)N1CC2C(CNc3ccc(N4CCOCC4)c(F)c3)C2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
PKM P14618 2/20 0.46
TSHR P16473 1/20 0.46
ALDH1A1 P00352 7/20 0.46
MAPT P10636 5/20 0.46
KDM4E B2RXH2 1/20 0.44
GAA P10253 2/20 0.44
LMNA P02545 4/20 0.43
HTT P42858 3/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
ALOX12 P18054 1/20 0.42
PKLR P30613 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4418890 0.89 MEN1 (0.47) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL4414159 0.88 SMN1; SMN2 (0.54) MEN1KMT2APKMALDH1A1GAA
SCHEMBL4419968 0.88 L3MBTL1 (0.46) MEN1KMT2AALDH1A1GAALMNA
SCHEMBL4425059 0.88 KMT2A (0.49) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL4413651 0.87 NPC1 (0.42) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL4425190 0.86 MEN1 (0.46) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL4414933 0.86 KMT2A (0.43) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL4417872 0.86 ALDH1A1 (0.45) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL4417782 0.86 MAPT (0.45) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL4413584 0.86 ALDH1A1 (0.48) KMT2APKMALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 MEN1 4107/4885KMT2A 1892/4885PKM 2551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.